The DOI matches its Crossref record; 35 of the 38 references it cites were found in a registry or an index; 22 of the 30 sources its claims cite were checked for support.
Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial
Open accessAbstract
The current third-line (and beyond) treatment options for RAS-mutant metastatic colorectal cancer have yielded limited efficacy. At the time of study start, the combination of sotorasib, a KRAS (Kirsten rat sarcoma viral oncogene homolog)-G12C inhibitor, and panitumumab, an epidermal growth factor receptor (EGFR) inhibitor, was hypothesized to overcome treatment-induced resistance. This phase 1b substudy of the CodeBreaK 101 master protocol evaluated sotorasib plus panitumumab in patients with chemotherapy-refractory KRASG12C-mutated metastatic colorectal cancer. Here, we report the results in a dose-exploration cohort and a dose-expansion cohort. Patients received sotorasib (960 mg, once daily) plus panitumumab (6 mg kg−1, once every 2 weeks). The primary endpoints were safety and tolerability. Secondary endpoints included efficacy and pharmacokinetics. Exploratory biomarkers at baseline were assessed. Forty-eight patients (dose-exploration cohort, n = 8; dose-expansion cohort, n = 40) were treated. Treatment-related adverse events of any grade and grade ≥3 occurred in 45 (94%) and 13 (27%) patients, respectively. In the dose-expansion cohort, the confirmed objective response rate was 30.0% (95% confidence interval (CI) 16.6%, 46.5%). Median progression-free survival was 5.7 months (95% CI 4.2, 7.7 months). Median overall survival was 15.2 months (95% CI 12.5 months, not estimable).
Overview
CoChat Summary
TL;DR
In this phase 1b CodeBreaK 101 substudy, sotorasib plus panitumumab was tolerable and showed promising efficacy in chemotherapy-refractory KRAS G12C-mutated metastatic colorectal cancer. Among 40 dose-expansion patients, confirmed ORR was 30.0%, median PFS 5.7 months, and median OS 15.2 months, with treatment-related grade ≥3 adverse events in 27% of all 48 patients.
Key findings
- Safety: among 48 treated patients, treatment-related adverse events of any grade occurred in 45 (94%) and grade ≥3 in 13 (27%); there were no grade 4 or 5 treatment-related events and no treatment-related discontinuations. No dose-limiting toxicities were observed in the 7 evaluable dose-exploration patients.
- Efficacy in the dose-expansion cohort (n=40): confirmed objective response rate 30.0% (95% CI 16.6–46.5), disease control rate 92.5% (95% CI 79.6–98.4), median duration of response 5.3 months (95% CI 2.8–7.4), median PFS 5.7 months (95% CI 4.2–7.7), and median OS 15.2 months (95% CI 12.5–not evaluable).
- Dose-exploration cohort (n=8): 1 confirmed partial response (12.5%; 95% CI 0.3–52.7) and disease control rate 75.0% (95% CI 34.9–96.8); among 5 patients with prior sotorasib treatment, 80.0% achieved stable disease.
- Baseline cfDNA alterations: most prevalent were APC (84%), TP53 (74%), SMAD4 (33%), PIK3CA (28%), and EGFR (26%). Median PFS was shorter with baseline BRAF alterations (2.9 vs 7.4 months) and ARID1A mutations (4.4 vs 7.4 months).
Methods
- Design: phase 1b, multicenter, open-label substudy of the CodeBreaK 101 master protocol (subprotocol H, Part 1 Cohort A and Part 2 Cohort A), with a dose-exploration cohort (n=8) and dose-expansion cohort (n=40); enrollment occurred June 24, 2020–December 21, 2021, with data cutoff January 4, 2023.
- Participants and treatment: adults with KRAS G12C-mutated metastatic colorectal cancer; dose-expansion patients had progression on or after fluoropyrimidine, oxaliplatin, irinotecan, and an antiangiogenic agent. Prior KRAS G12C inhibitor was permitted only in dose exploration. All patients received sotorasib 960 mg once daily plus panitumumab 6 mg/kg every 2 weeks.
- Endpoints and analysis: primary endpoints were safety and tolerability (dose-limiting toxicities within 28 days and adverse events per CTCAE v5.0); secondary endpoints included ORR, DCR, duration of response, time to response, PFS, OS per RECIST v1.1 by investigator assessment, and pharmacokinetics. Exploratory baseline cfDNA was assessed with the 74-gene Guardant360 test. Descriptive statistics, Clopper-Pearson exact CIs, and Kaplan-Meier methods were used.
Limitations
- Stated in the paper: this was a single-arm study; efficacy endpoints were based on investigator assessment rather than blinded independent central review; and the exploratory analysis of genomic co-alterations was not statistically powered.
- Evident from the text: the sample size was small, subgroup analyses (e.g., BRAF/ARID1A alterations, tumor sidedness, region) had overlapping CIs, and the dose-exploration cohort was confounded by prior KRAS G12C inhibitor treatment in 5 of 8 patients.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
12 Valid · 3 Not valid · 6 Not checked · 72 Own results and interpretations
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Our observation that the combination of sotorasib plus panitumumab showed similar efficacy regardless of primary tumor location is consistent with data for BRAF and EGFR inhibitor combination in BRAFV600E metastatic colorectal cancer 22 , although owing to the small sample sizes and overlapping CIs in this subgroup analysis, these results must be interpreted with caution.”
What the sources say
- Could not verifycites [22] Tabernero, J. et al. Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: the phase 3 randomized SUNLIGHT study. J. Clin. Oncol. 41, 4-4 (2023). sourceExperimental — accuracy not yet measured
The unpaginated abstract field in our copy reports results for trifluridine/tipiracil plus bevacizumab, not BRAF and EGFR inhibitor combination. Searches for BRAF V600E and efficacy by primary tumor location found no passage addressing the comparison attributed to this source. (LLM, conf=0.76)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These findings that a combination approach is more effective than either agent alone is generally consistent with that of the recent phase 2 nonrandomized KRYSTAL-1 trial that tested the combination of the KRAS G12C inhibitor adagrasib with cetuximab in KRAS G12C mutated colorectal cancer. 18”
What the sources say
- Partly supportedcites [18] Yaeger, R. et al. Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C. N. Engl. J. Med. 388, 44–54 (2023). sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In this KRAS G12C-mutated population where patients were not expected to respond to panitumumab, these results provide a proof of principle that sotorasib and an anti-EGFR antibody work synergistically as observed in preclinical studies. 16,17”
What the sources say
- Supportedcites [16] Ryan, M. B. et al. KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy. Cell Rep. 39, 110993 (2022). source
The Results section (page unavailable) reports that AMG 510 (sotorasib) plus panitumumab improved responses over AMG 510 alone in several preclinical KRAS G12C-mutant colorectal cancer models. The paper notes that the benefit varied across models; it supports the cited preclinical rationale, not the citing authors’ conclusion about their patients. (LLM, conf=0.85)
- Supportedcites [17] Amodio, V. et al. EGFR blockade reverts resistance to KRASG12C inhibition in colorectal cancer. Cancer Discov. 10, 1129–1139 (2020). source
The preclinical cell-line experiments (p. 6) report that cetuximab, an anti-EGFR antibody, synergized with AMG510 (sotorasib) in KRAS G12C colorectal cancer models. The Discussion (p. 9) notes that cetuximab and panitumumab are approved for RAS/RAF wild-type colorectal cancer, consistent with the expectation that panitumumab alone would not benefit this KRAS-mutated population. The citing authors’ characterization of their own results as proof of principle is not a finding attributed to this source. (LLM, conf=0.92)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No treatment-related adverse events led to discontinuation of either drug.”
- Also stated in: § Discussion · p. 8 · plain
“No treatment-related adverse events were grade 4 or 5 or led to treatment discontinuation of either agent.”
plainn = 48- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Discussion · p. 8 · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Treatment-related adverse events of any grade and grade ≥3 occurred in 45 (94%) and 13 (27%) patients, respectively.”
- Also stated in: § Safety · p. 6 · plain
“Among 48 patients, treatment-related adverse events of any grade and grade ≥3 were observed in 45 (94%) and 13 (27%) patients, respectively”
plainn = 48- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Safety · p. 6 · plain
44 more claims
Create a free account to see all 93 claims and every source verdict.
- Probably not a substantial claim. 30
- It may state two separate claims as one. 19
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Similarly, phase I/II data for other KRASG12C inhibitors in colorectal cancer demonstrated greater activity in combination with anti-EGFR antibodies versus monotherapy (17–21).”
From Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer (2024) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Irinotecan | 7 (88) | 40 (100) | 46 (96) |”
Reported 46 · recomputed 47
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Bevacizumab | 8 (100) | 39 (98) | 45 (94) |”
Reported 45 · recomputed 47
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Efficacy · p. 7
“The median duration of treatment was 6.0 months (range: 0.5-18.9).”
§ Efficacy · p. 7
“Three patients remained on treatment at data cutoff and had received the combination for 15.6-19.2 months.”
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303
THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
CLOPPER, C. J., & PEARSON, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,003
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895 · cited 1×
“3c). and overall survival of 6.4 months for regorafenib and 7.1 months for trifluridine–tipiracil 4,5 .”
InfluentialThe Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277 · cited 10×
“Prior treatment with a KRAS-G12C inhibitor was permitted only in the dose-exploration cohort.”
InfluentialSelf-citationDe Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Arain, M. A., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Farkas, L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0012 · Cited by 1,696
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Mayer, R. J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., Yamazaki, K., Shimada, Y., Tabernero, J., Komatsu, Y., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414325 · Cited by 1,431 · cited 1×
“3c). and overall survival of 6.4 months for regorafenib and 7.1 months for trifluridine–tipiracil 4,5 .”
InfluentialTabernero, J., Grothey, A., Van Cutsem, E., Yaeger, R., Wasan, H., Yoshino, T., Desai, J., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02088 · Cited by 569 · cited 1×
“These findings are analogous to the outcomes observed when a BRAF inhibitor was combined with an anti-EGFR antibody to treat BRAF V600E -mutated metastatic colorectal cancer, implying that inhibition of an overactive RAS–BRAF–MAPK pathway requires concurrent EGFR inhibition 20 .”
Self-citationAdagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
Yaeger, R., Weiss, J., Pelster, M. S., Spira, A. I., Barve, M., Ou, S.-H. I., Leal, T. A., Bekaii-Saab, T. S., Paweletz, C. P., Heavey, G. A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212419 · Cited by 527 · cited 3×
“This finding that a combination approach is more effective than either agent alone is generally consistent with that of the recent phase 2 nonrandomized KRYSTAL-1 trial, which tested the combination of the KRAS-G12C inhibitor adagrasib with cetuximab in KRAS G12C -mutated colorectal cancer 18 .”
Self-citation
Cited by
Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Adam, M., Chang, G., Chen, Y.-J., Ciombor, K. K., Cohen, S. A., Cooper, H. S., Deming, D., Garrido-Laguna, I., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0029 · Cited by 371
KRAS inhibitors: resistance drivers and combinatorial strategies
Isermann, T., Sers, C., Der, C. J., & Papke, B. (2025) · Trends in Cancer · doi:10.1016/j.trecan.2024.11.009 · Cited by 196
Yaeger, R., Uboha, N. V., Pelster, M. S., Bekaii-Saab, T. S., Barve, M., Saltzman, J., Sabari, J. K., Peguero, J. A., Paulson, A. S., Jänne, P. A., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0217 · Cited by 139
Self-citationCombinatorial strategies to target RAS-driven cancers
Perurena, N., Situ, L., & Cichowski, K. M. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00679-6 · Cited by 110
KRAS G12C inhibitor combination therapies: current evidence and challenge
Miyashita, H., Kato, S., & Hong, D. S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1380584 · Cited by 103
Self-citation
Metadata
- Authors
- Kuboki, Y., Fakih, M., Strickler, J., Yaeger, R., Masuishi, T., Kim, E. J., Bestvina, C. M., Kopetz, S., Falchook, G. S., Langer, C., Krauss, J., Puri, S., Cardona, P., Chan, E., Varrieur, T., Mukundan, L., Anderson, A., Tran, Q., & Hong, D. S.
- Affiliations
- National Cancer Center Hospital East (JP)
- City Of Hope National Medical Center (US)
- Duke Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- Aichi Cancer Center Hospital (JP)
- UC Davis Comprehensive Cancer Center (US)
- University of Chicago (US)
- The University of Texas MD Anderson Cancer Center (US)
- Sarah Cannon (US)
- University of Pennsylvania (US)
- University of Michigan (US)
- Huntsman Cancer Institute (US)
- Amgen (United States) (US)
- Corresponding author
- Hong, David S.
- ORCID
- Venue
- Nature Medicine
- Published
- 2024-01
- Volume
- 30
- Issue
- 1
- Pages
- 265-270
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC11135132
- OpenAlex
- W4390582065
- Cited by
- 103
- References
- 38
- Citations by year
- 2026: 38 · 2025: 38 · 2024: 27
- FWCI
- 17.53
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- Amgen
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- sotorasib, panitumumab, KRAS G12C mutation, metastatic colorectal cancer, chemotherapy-refractory disease, treatment resistance, objective response rate, progression-free survival, overall survival, safety and tolerability, pharmacokinetics, APC, TP53, SMAD4
- MeSH terms
- Panitumumab, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Humans, Mutation, Piperazines, Pyridines, Pyrimidines, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial. https://app.cochat.ai/papers/10.1038/s41591-023-02717-6
- The paper
- Kuboki, Y., Fakih, M., Strickler, J., Yaeger, R., Masuishi, T., Kim, E. J., Bestvina, C. M., Kopetz, S., Falchook, G. S., Langer, C., Krauss, J., Puri, S., Cardona, P., Chan, E., Varrieur, T., Mukundan, L., Anderson, A., Tran, Q., & Hong, D. S. (2024). Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial. Nature Medicine. https://doi.org/10.1038/s41591-023-02717-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.